Novo-Nordisk A/S (NVO) Earnings Date & Reports

Key Takeaways

• Novo Nordisk beat consensus estimates on both revenue and earnings, with adjusted sales rising 7% at constant exchange rates (CER) to DKK 78.5 billion and adjusted operating profit climbing 11%.
• The oral Wegovy pill surpassed 5 million cumulative U.S. prescriptions since its January launch, cementing its status as the fastest GLP-1 drug launch by volume in the company's history.
• Gross margin contracted to 78.2% from 82.7% a year earlier, reflecting lower realized prices, unfavorable currency effects, and manufacturing costs, including roughly DKK 3 billion in one-time right-sizing expenses.
• The company raised its full-year 2026 outlook, narrowing the expected decline in adjusted sales and operating profit to a range of 0% to -6% from the prior range of -4% to -12%.
• NVO shares dropped approximately 6% despite the earnings beat, as investors focused on softer-than-expected Wegovy pill sales, pipeline setbacks, and an outlook that still allows for a contraction in 2026.
• Pipeline headwinds intensified with the discontinuation of monlunabant, a non-cash impairment charge of DKK 6.3 billion, and mixed clinical results for next-generation obesity candidate CagriSema.

Earnings Context and Why It Matters

Novo Nordisk's second-quarter 2026 earnings arrived at a critical juncture for the Danish pharmaceutical giant. Once the undisputed frontrunner in the booming GLP-1 (glucagon-like peptide-1) market for diabetes and obesity treatment, the company has faced mounting pressure from rival Eli Lilly, which has steadily gained market share with its competing drugs Mounjaro and Zepbound. Coming into this report, Novo Nordisk's U.S.-listed ADR (American Depositary Receipt) shares had already shed roughly 9% year-to-date, weighed down by pricing headwinds, declining U.S. sales, and disappointing clinical trial results. These quarterly results offered management an opportunity to reset the narrative around the Wegovy product portfolio, oral drug uptake, and the broader growth trajectory in a market expected to exceed $100 billion in annual revenue by 2030.

Reported Results

Novo Nordisk reported second-quarter 2026 net sales of DKK 78.49 billion (approximately $12.1 billion), representing a 3% increase at CER on a reported basis and a 7% increase on an adjusted basis, which excludes a non-recurring 340B Drug Pricing Program rebate reversal from the prior-year period. Adjusted revenue handily beat the consensus estimate of roughly $10.94 billion. Adjusted operating profit reached DKK 33.39 billion, up 11% at CER, also exceeding analyst expectations.

On a per-share basis, adjusted earnings per ADR came in at approximately $0.96, well above the Zacks Consensus Estimate of $0.82 and the broader analyst consensus of roughly $0.78. Reported net income, however, fell to DKK 20.99 billion from DKK 26.50 billion a year earlier, weighed down by DKK 6.3 billion in non-cash impairment charges tied to pipeline intangible assets — including DKK 4.0 billion related to the now-discontinued monlunabant program.

By segment, Obesity Care was the standout performer, with sales rising 15% to DKK 23.15 billion on an adjusted basis. Diabetes Care sales slipped 1% to DKK 50.43 billion, while Rare Disease contributed a modest 3% increase to DKK 4.91 billion. Within the obesity portfolio, the injectable Wegovy formulation generated DKK 19.48 billion in sales — flat year-over-year — while the newly launched oral Wegovy pill contributed DKK 3.22 billion (roughly $500 million), slightly below the FactSet consensus estimate of DKK 3.27 billion. Ozempic, the company's flagship diabetes drug, remained flat at DKK 31.38 billion.

Gross margin compressed notably to 78.2%, down from 82.7% in the prior-year quarter, reflecting persistent pricing pressure, a shift toward lower-priced cash-pay channels, and approximately DKK 3 billion in one-time manufacturing right-sizing costs. International operations outperformed the U.S., posting 10% adjusted growth at CER compared to 4% in the American market, where injectable Wegovy sales fell 22% due to lower net realized prices despite higher volumes.

AI Screener

For investors seeking to identify stocks with similar earnings momentum or evaluate new opportunities across the pharmaceutical sector, Tickeron's AI Screener offers a powerful AI-driven discovery tool. The platform allows users to scan thousands of stocks and ETFs using customizable filters such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. Whether tracking breakout candidates, screening for fundamental strength, or monitoring trend shifts, the AI Screener helps traders and investors surface actionable ideas with greater speed and precision than manual screening methods. Explore the tool to complement your earnings season research with data-driven market insights.

Market Reaction and Investor Sentiment

Despite delivering a clear beat on both the top and bottom lines, Novo Nordisk's U.S.-listed shares fell roughly 6% on August 4, closing near $44.28. The selloff reflected a convergence of investor concerns that outweighed the headline numbers. First, the oral Wegovy pill — widely viewed as the company's most important near-term growth catalyst — generated DKK 3.22 billion in sales, marginally below the DKK 3.27 billion consensus, and the miss, however small, rattled confidence in the ramp trajectory. Second, U.S. injectable Wegovy sales remained under pressure, down 22% at CER, as competition from Eli Lilly's Zepbound continued to erode market share and pricing power. Third, the company took a significant non-cash pipeline impairment and confirmed the termination of monlunabant development, while the CagriSema program showed only non-inferiority — not superiority — versus Lilly's tirzepatide in the REIMAGINE 4 study. Finally, the raised guidance still projects a potential decline in both sales and operating profit for the full year, reinforcing the narrative that 2026 remains a transition year for the company. Copenhagen-listed shares fell as much as 5% in early trading before partially recovering.

Forward Outlook and Key Factors to Monitor

Looking ahead, Novo Nordisk's improved guidance sets a more constructive tone, but several variables will determine whether the second-half recovery gains traction. The company now expects adjusted sales and operating profit growth at CER to range between 0% and -6%, with free cash flow projected at DKK 45–55 billion. The upgraded outlook is anchored in continued strong GLP-1 volume growth, particularly from the Wegovy pill, which recently launched in the United Kingdom — capturing approximately 300,000 patients within three weeks — and the United Arab Emirates, with further international launches expected.

Pricing dynamics in the United States remain a central concern. The company is navigating reduced Medicaid coverage for anti-obesity medicines in several states, a shift toward lower-priced cash-pay channels, and the lingering impact of a U.S. government pricing agreement that expands Medicare and Medicaid access but compresses net realized prices. Adding to the complexity, Novo Nordisk previously announced a major U.S. list-price reduction effective January 1, 2027, which will cut wholesale acquisition costs across the Wegovy and Ozempic portfolios by roughly 35% to 50%. While aimed at expanding patient access, this move introduces additional uncertainty into the 2027 revenue outlook.

On the pipeline front, investors should monitor regulatory decisions on CagriSema and progress on amycretin, a dual-action GLP-1 and amylin receptor agonist being developed in both injectable and oral formulations. The recent failure of the ZEUS phase III cardiovascular outcomes trial for ziltivekimab — which will trigger a further non-cash impairment charge in the third quarter — narrows the company's diversification path beyond GLP-1 therapies. With Eli Lilly now commanding a market capitalization above $1 trillion and growing its GLP-1 franchise at a faster clip, Novo Nordisk's ability to execute on oral drug adoption, defend injectable market share, and deliver on next-generation pipeline assets will be critical in shaping investor sentiment through the remainder of 2026 and into 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations